Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 16Other hematologic neoplasm 13Plasma cell 8Thoracic 7Gynecologic 3Gastrointestinal 3Dermatologic 2Tumor-Agnostic 1Myeloid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 581Carboplatin 527Cisplatin 355Bevacizumab 256pembrolizumab 226Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 126Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 90niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 73Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 56Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Maintenance × Gynecologic × Clear all
NCT06827353 2025-02-14

OVNI-B

Centre Hospitalier Universitaire de Nīmes

Recruiting
300 enrolled
Gynecologic

Carcinoma, Ovarian Neoplasms

NCT06714084 2024-12-03

CNCMT

Hubei Cancer Hospital

Phase NA Enrolling by invitation
20 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
167 enrolled
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡